CervoMed Inc. - 8-K Filing
CervoMed presented new clinical data at AAIC showing neflamapimod's potential for treating dementia with Lewy bodies. (Items: 7.01 Regulation FD Disclosure On July 14, 2026, CervoMed Inc, 8.01 The information set forth in the first and third paragraphs of, and under the headings “Analyses Reinforce Observed Treatment Effect of Nefla, 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No)
Tickers: $CRVO